Ipsen

Last updated

Ipsen
Company typePublic
Euronext Paris:  IPN
CAC Mid 60 Component
ISIN FR0010259150
Industry Pharmaceutical
Founded1929
FounderHenri Beaufour
HeadquartersBoulogne-Billancourt, France
Key people
 Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
ProductsList of medicines
RevenueIncrease2.svg€3.128 billion(2023) [1]
Increase2.svg€1.001 billion(2023) [1]
Increase2.svg€647 million(2023) [1]
Number of employees
5,700 [1]
Websitewww.ipsen.com
Footnotes /references
[1]

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. [2] [3]

Contents

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). [4] [5] The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. [6]

History

In 1929, Dr. Henri Beaufour founded the Beaufour Laboratories in Dreux. The first product marketed was Romarene, a rosemary-based medicine intended for the treatment of digestive disorders, discontinued from the market in 2011.

In the 1950s and 1960s, Laboratoires Beaufour underwent a phase of expansion. In 1954, the group launched betaine citrate, used in the symptomatic treatment of dyspepsia. Henri Beaufour's two sons, Albert and Gérard Beaufour, joined the company. [6] The group opened a factory in Dreux in 1961, [7] and another in L'Isle- sur-la-Sorgue in 1965. A research center opened in Plessis-Robinson the same year.

In the 1970s and 1980s, Laboratoires Beaufour created a subsidiary, Ipsen (1975), and began to internationalize its activities. In 1976, the company opened a research center in Milford (Massachusetts) in the U.S. In 1977, the group launched Smecta (diosmectite clay, a gastrointestinal bandage and anti-diarrhoeal agent). [7]

In 1983, the group created the Fondation Ipsen under the aegis of the Fondation de France, to encourage exchanges between scientists in the field of life sciences. [8]

In 1986, the group launched Decapeptyl, [7] used to treat certain pathologies influenced by sex hormones, such as prostate cancer, endometriosis, uterine fibroids and early puberty.

In the 1990s, the group diversified its activity and continued its international expansion. In 1990, an industrial center was created in Signes, in the Var department. In 1992, the group opened a subsidiary in China. In 1994, the group launched Dysport (type A botulinum toxin for the treatment of muscle spasms) after acquiring the British company Speywood (then called Porton International). [9] The same year, the group opened a subsidiary in Russia.

In 1995, the group launched Somatuline, [7] used to treat hypersecretion of growth hormones (acromegaly) and in neuro-endocrine tumors, and in 1996, Forlax [7] was launched.

In 2000, after the death of Albert Beaufour, the company was taken over by his children, Anne Beaufour and Henri Beaufour.

In 2003, the company changed its name to Ipsen [10] and in 2005, it was listed on the Paris Stock Exchange [11] on Euronext. In 2004, the company inaugurated a new botulinum toxin production unit in Wrexham (UK). In 2007, the company established a partnership with Galderma for botulinum toxin type A products in aesthetic medicine. In addition, somatuline was granted marketing authorization in the United States for the treatment of acromegaly.

In 2007, Ipsen shares were included in the SBF 120 stock market index.

In 2007, Dysport was granted marketing authorization in the United States for certain indications in therapeutic and aesthetic medicine. Decapeptyl 6-month formulation receives marketing authorization in 9 European countries from the European Medicines Agency.

In 2011, Ipsen announced a new strategy focusing on several areas, including a refocus on specialty medicine, research and development and international development. [4] In 2013, Ipsen acquired the British company Syntaxin, a leader in the engineering of recombinant botulinum toxin11. In 2014, the company participated in the creation of a joint laboratory with the CNRS – Archi-Pex -, the Commissariat à l'énergie atomique et aux énergies alternatives and the University of Rennes1, with the aim of designing and developing hormone peptides.

In 2015, Ipsen inaugurated a research and development center in Cambridge, Massachusetts. [12]

In 2016, Dysport Injection was approved in the United States for the treatment of lower limb spasticity in children aged two years and older. [13]

In 2016, Ipsen licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line treatment of advanced renal cell carcinoma. In January 2017, Ipsen announced the acquisition of certain assets of Merrimack Pharmaceuticals, including Onivyde, for the treatment of pancreatic and ovarian cancer. [14]

In 2019, Ipsen acquired Montreal-based Clementia Pharmaceuticals, specializing in rare bone diseases, [15] , [16] ,. [17] Clementia brought a drug candidate, palovarotene, to Ipsen for a rare genetic disease, fibrodysplasia ossificans progressiva (FOP).

In February 2022, Ipsen announced the proposed sale of the Consumer HealthCare (CHC) division after entering into exclusive negotiations with the French laboratory Mayoly Spindler. [18]  In July 2022, Ipsen completed the divestment of the CHC business to Mayoly Spindler.

In August 2022, Ipsen successfully completed the acquisition of Epizyme and its lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor for adults with relapsed or refractory follicular lymphoma (FL), which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020. As part of the transaction, Ipsen also acquired Epizyme's first-in-class, oral SETD2 inhibitor development candidate.

In January 2023, Ipsen announced it would acquire rare disease specialist Albireo for $952m, bringing into its portfolio Bylvay (odevixibat), a non-systemic ileal bile acid transport inhibitor for the treatment of paediatric patients with pruritus in progressive familial intrahepatic cholestasis (PFIC). [19] [20]

In August 2023, The U.S. Food and Drug Administration (FDA) approved Sohonos for the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic connective tissue disease that causes progressive loss of mobility and shortened life expectancy, in adults and children. It can be used for girls aged 8 years and older and boys aged 10 years and older. The estimated annual cost of the drug is from $624,000. The disease occurs in 1 in 1,600,000 newborns, with about 800 people now known to have the disease. [21]

In February 2024, Ipsen received FDA approval for Onivyde (irinotecan liposome injection), which is used in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (mPDAC). Pancreatic cancer accounts for approximately 3% of all cancer diagnoses in the United States and approximately 7% of all cancer deaths. PDAC is the most common form of the disease, with more than 60,000 diagnoses in the United States each year and approximately 500,000 diagnoses worldwide. [22]

In June 2024, Ipsen received accelerated approval from the US FDA for Iqirvo elafibranor based on positive Phase III ELATIVE trial data. elafibranor is a treatment for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. [23] [24]

Contriversaries

As of March 2022, Ipsen announced the suspension of certain promotional activities in Russia, including advertising and participation in non-scientific congresses. Additionally, the company decided not to initiate any new clinical trials in the country. Despite Russian invasion in Ukraine, Ipsen continues to serve patients in Russia, maintaining the availability of its existing medications. [25]

Financial Data

Financial data in EUR millions
Year201720182019202020212022 [26] 2023 [27]
Total sales1,908.72,224.82,576.22,591.62,643.33,025.03,127.5
Change vs prior year – at actual exchange rates21.1%16.6%15,8%3.5%10.7%14.4%3.4%
Core operating margin20.8%29.7%30,4%32,0%35.2%36.9%32.0%
Employees5,4005,7005,8005,7005,7005,7005,700

Shareholding

Ownership of Ipsen's share capital (% of total capital) as of 31 December 2022: [28]

Name % of total capital
Free float40.86%
Beach Tree26.03%
Highrock26.03%
MR Schwabe4.34%
Treasury shares1.3%
Finvestan0.22%
Other registered shareholders0.79%
Employee0.25%
Directors (others)0.17%

Medicines

In Oncology

Cabometyx [29] ( cabozantinib ) is a tyrosine kinase inhibitor (TKI) used in the treatment of advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma) in adults previously treated with the medicine sorafenib, as well as in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) after prior systemic therapy

Decapeptyl [29] ( triptorelin ) is an analogue of the natural gonadotropin-releasing hormone (GnRH), approved for the treatment of locally advanced metastatic prostate cancer, central precocious puberty (CPP), endometriosis, uterine fibroma, and in-vitro fertilization, and used as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor for women at high-risk of breast cancer recurrence.

Somatuline [29] (lanreotide ) is a synthetic version of the natural hormone somatostatin, which is found naturally in the human body. Used for the treatment of neuroendocrine tumors (NETs), carcinoid syndrome or acromegaly.

Onivyde [29] ( irinotecan liposome injection) is prescribed in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Tazverik is an inhibitor of the enzyme EZH2 (enhancer of zeste homologue 2) used to treat follicular lymphoma, which is a cancer of the immune system, as well as epithelioid sarcoma which is a rare, slow-growing type of soft tissue cancer which often begin in the soft tissue under the skin of a finger, hand, forearm, lower leg or foot, and in the abdomen or pelvic area.

These indications are approved under FDA accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Rare Disease

Increlex [29] (mecasermin) injection is a prescription medicine used to treat children who are very short for their age because their bodies do not make enough IGF-1. This condition is called primary IGF-1 deficiency.

Sohonos [30] ( palovarotene ) is an oral investigational, selective retinoic-acid receptor gamma (RARγ) agonist being developed as a potential treatment for people living with the debilitating ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP).

In Neuroscience

Dysport [29] ( Botulinum toxin ) is a prescription medicine used for pathologies characterized by involuntary and uncomfortable muscle contractions (dystonias: blepharospasm, spasmodic torticollis, hemifacial spasm; spasticity: spasticity of the upper or lower limb, dynamic deformation of the equine foot). This drug is also used in aesthetic medicine to temporarily reduce certain wrinkles.

Fondation Ipsen

The Fondation Ipsen pour la recherche thérapeutique, created in 1983 under the aegis of the Fondation de France, supports work in the field of therapeutic research. In particular is focused on helping improve the lives of patients with rare diseases. [8]

It has contributed to numerous major advances in biological and medical research, organized scientific conferences, and produced literature and content to help patients and the wider community understand rare diseases.

Since 2007, Fondation Ipsen has initiated several series of meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the DMMGF (Days of Molecular Medicine Global Foundation), as well as with the journals Nature, Cell and Science. The Fondation Ipsen has published more than 100 books and awarded more than 250 prizes and grants.

In 2021, Fondation Ipsen worked directly with 146 organizations to assess the needs of patients with rare diseases. Fondation Ipsen and Science Magazine organized 9 webinars with the world's leading specialists in rare diseases, as well as policymakers from all over the world.The webinars addressed a variety of essential topics for patients living with rare diseases and their families. The webinars received such a strong response that Science Magazine and the Fondation now co-publish an international magazine for the rare disease community: The Rare Disease Gazette.

Related Research Articles

<span class="mw-page-title-main">Botulinum toxin</span> Neurotoxin produced by Clostridium botulinum

Botulinum toxin, or botulinum neurotoxin, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent.

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

<span class="mw-page-title-main">Fibrodysplasia ossificans progressiva</span> Disease in which fibrous connective tissue turns into bone

Fibrodysplasia ossificans progressiva, also called Münchmeyer disease or formerly myositis ossificans progressiva, is an extremely rare connective tissue disease in which fibrous connective tissue such as muscle, tendons, and ligaments turn into bone tissue (ossification). It is the only known medical condition where one organ system changes into another. It is a severe, disabling disorder with no cure.

<span class="mw-page-title-main">Sitagliptin</span> Diabetes medication

Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin.

<span class="mw-page-title-main">Panobinostat</span> Chemical compound

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor.

<span class="mw-page-title-main">BioCryst Pharmaceuticals</span> American pharmaceutical company

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

<span class="mw-page-title-main">Olaparib</span> Chemical compound (cancer therapy drug)

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

<span class="mw-page-title-main">Crizotinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK and ROS1 inhibitor.

<span class="mw-page-title-main">Elafibranor</span> Chemical compound

Elafibranor (INN), sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis.

<span class="mw-page-title-main">Palovarotene</span> Chemical compound

Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist. It is taken by mouth.

Advanced Accelerator Applications is a France-based pharmaceutical group, specialized in the field of nuclear medicine. The group operates in all three segments of nuclear medicine to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.

Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

<span class="mw-page-title-main">Sacituzumab govitecan</span> Antibody-drug conjugate

Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.

<span class="mw-page-title-main">FOP Friends</span>

FOP Friends, formerly Friends of Oliver, is a registered charity in the United Kingdom established on 1 March 2012. It aims to raise funds that are needed to find effective treatments for the rare genetic condition fibrodysplasia ossificans progressiva (FOP). The charity also works to raise awareness and understanding of FOP amongst medical communities and the general public.

<span class="mw-page-title-main">Merrimack Pharmaceuticals</span> Company in Cambridge, United States

Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.

<span class="mw-page-title-main">Tazemetostat</span> Chemical compound

Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

<span class="mw-page-title-main">Eileen Shore</span> American medical researcher

Eileen M. Shore is an American medical researcher and geneticist specializing in research of muscoskeletal disorders such as fibrodysplasia ossificans progressiva.

<span class="mw-page-title-main">Belzutifan</span> Chemical compound

Belzutifan, sold under the brand name Welireg, is an anti-cancer medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It is taken by mouth. Belzutifan is an hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.

<span class="mw-page-title-main">Odevixibat</span> Medication

Odevixibat, sold under the brand name Bylvay among others, is a medication for the treatment of progressive familial intrahepatic cholestasis. It is taken by mouth. Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). It was developed by Albireo Pharma.

References

  1. 1 2 3 4 5 "FY 2023 results" (PDF). Ipsen.
  2. ↑ "Ipsen: A dynamic, fast-growing specialty care powerhouse".
  3. ↑ "Ipsen | Evaluate".
  4. 1 2 "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
  5. ↑ "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
  6. 1 2 France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". lechorepublicain.fr. Retrieved 13 December 2022.
  7. 1 2 3 4 5 Mariette Finet & Elisabeth Hennebert (2021). From Beaufour to Ipsen. Qualibris Edition.
  8. 1 2 "Rare Disease Foundation – Homepage". Fondation Ipsen. Retrieved 13 December 2022.
  9. ↑ Nouvelle, L'Usine (10 November 1994). "PharmacieBeaufour-Ipsen s'installe outre-Manche avec PortonConnu pour sa recherche, Porton International va ouvrir au septième groupe pharmaceutique français les marchés britannique et américain. Le ticket d'entrée: 550millions de francs" (in French).{{cite journal}}: Cite journal requires |journal= (help)
  10. ↑ Nouvelle, L'Usine (29 May 2003). "Ipsen succède à Beaufour Ipsen" (in French).{{cite journal}}: Cite journal requires |journal= (help)
  11. ↑ "IPSEN €100.40 | Euronext exchange Live quotes". live.euronext.com. Retrieved 13 December 2022.
  12. ↑ "Aux États-Unis, Ipsen transfère ses activités de R&D à Cambridge, Massachusetts, en 2014". businesswire.com. 26 September 2013. Retrieved 13 December 2022.
  13. ↑ "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 9 November 2023.
  14. ↑ "France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal". Reuters. 8 January 2017. Retrieved 9 November 2023.
  15. ↑ "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion". Reuters. 25 February 2019. Retrieved 13 December 2022.
  16. ↑ Bourse, Zone (18 April 2019). "Ipsen boucle son acquisition record du canadien Clementia | Zonebourse". zonebourse.com (in French). Retrieved 13 December 2022.
  17. ↑ Nouvelle, L'Usine (18 April 2019). "Avec l'acquisition de Clementia, Ipsen se renforce dans les maladies rares" (in French).{{cite journal}}: Cite journal requires |journal= (help)
  18. ↑ "Ipsen relève ses objectifs pour 2024 et négocie la vente de son pôle santé familiale". Investir (in French). 11 February 2022. Retrieved 13 December 2022.
  19. ↑ Dunleavy, Kevin (9 January 2023). "JPM23: Ipsen scoops up liver disease specialist Albireo for $952M". Fierce Pharma. Retrieved 31 January 2023.
  20. ↑ "Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases". Ipsen. Retrieved 31 January 2023.
  21. ↑ "US FDA Approves French Drugmaker Ipsen's Rare Bone Disorder Drug". US News. Archived from the original on 17 August 2023. Retrieved 13 March 2024.
  22. ↑ "Ipsen Nabs FDA Approval for NALIRIFOX in First-Line Metastatic Pancreatic Adenocarcinoma". Pharmaceutical Commerce. Archived from the original on 13 March 2024. Retrieved 11 March 2024.
  23. ↑ Ipsen (9 May 2024). A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid (Report). clinicaltrials.gov. Archived from the original on 2 May 2024. Retrieved 11 June 2024.
  24. ↑ "Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis". wallstreet-online.de (in German). 10 June 2024. Archived from the original on 11 June 2024. Retrieved 11 June 2024.
  25. ↑ "Ipsen". Leave Russia. Retrieved 10 December 2024.
  26. ↑ "Strong Full-Year 2022 Results and Guidance for 2023 | Ipsen Global". Global. Retrieved 11 June 2024.
  27. ↑ "Building on solid FY 2023 results, Ipsen anticipates four launches in 2024". Global. Retrieved 11 June 2024.
  28. ↑ "Shareholders Information at Ipsen | Valuable Insights for Shareholders". Global. Retrieved 11 June 2024.
  29. 1 2 3 4 5 6 "Our Products". Ipsen. Retrieved 13 December 2022.
  30. ↑ "Research and Development". Ipsen. Retrieved 13 December 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.